Traders Purchase Large Volume of Call Options on Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of unusually large options trading activity on Thursday. Stock traders bought 12,429 call options on the company. This is an increase of 579% compared to the typical volume of 1,830 call options.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. The Goldman Sachs Group set a $12.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, February 18th. Finally, Cantor Fitzgerald started coverage on shares of Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.71.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $7.73 on Friday. The firm has a market cap of $141.77 million, a price-to-earnings ratio of -0.47 and a beta of 0.13. The stock’s fifty day moving average price is $7.90 and its two-hundred day moving average price is $6.85. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.03. The firm had revenue of $34.08 million for the quarter, compared to analyst estimates of $33.16 million. On average, equities analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC bought a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at $74,000. Baird Financial Group Inc. bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth $45,000. State Street Corp lifted its position in shares of Karyopharm Therapeutics by 27.2% during the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock worth $434,000 after buying an additional 12,600 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Karyopharm Therapeutics in the fourth quarter valued at about $95,000. Finally, XTX Topco Ltd acquired a new stake in Karyopharm Therapeutics in the second quarter valued at about $56,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.